Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.

Abstract

Antibiotic safety is a major determinant in osteomyelitis therapy. Limited data is available describing the long-term safety and efficacy of daptomycin. the safety population was drawn from CORE 2005 and 2006, a retrospective, observational, multicenter study. Clinically evaluable patients received >3 days of daptomycin appropriately adjusted for renal function. three hundred twenty-seven patients were evaluated for safety; 188 (57%) >or=6 mg/kg, 139 (43%) <6 mg/kg. Thirty-one (10%) patients experienced adverse events possibly related to daptomycin and the incidence was similar regardless of dose. No difference was observed in the rate of creatine phosphokinase elevations by dose. A trend toward higher improved rates was noted in patients receiving a final dose of >or=6mg/kg (96% vs. 90%, P=0.08). Daptomycin appeared well-tolerated at doses of 6 mg per kg or greater which were associated with greater clinical improvement. These results require verification via a prospective clinical trial.

• Authors: J A Crompton, D S North, S A McConnell, K C Lamp
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 21 Issue 4 Pg. 414-20 (Aug 2009) ISSN: 1973-9478 [Electronic] England
• PMID: 19622460 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Daptomycin

Topics

• Adult
• Aged
• Anti-Bacterial Agents (therapeutic use)
• Daptomycin (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Osteomyelitis (drug therapy)
• Retrospective Studies
• Safety
• Treatment Outcome